Skip to main content

Table 2 Incidence of bone metastases and mortality

From: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

  Clodronate (n = 530) Placebo (n = 539) Hazard ratio (95% CI) P value
Bone metastases (all patients)     
   2 years 19 (3.6%) 35 (6.5%) 0.546 (0.312, 0.954) 0.031
   5 years 51 (9.6%) 73 (13.5%) 0.692 (0.484, 0.990) 0.043
Bone metastases (stage II/III)     
   n 352 357   
   2 years 16 (3.0%) 32 (6.0%) 0.496 (0.272, 0.975) 0.020
   5 years 39 (7.4%) 64 (11.8%) 0.592 (0.398, 0.882) 0.009
Visceral metastases     
   2 years 39 (7.3%) 47 (8.7%) 0.84 (0.55,1.29) 0.428
   5 years 79 (14.9%) 94 (17.4%) 0.84 (0.62,1.13) 0.241
Visceral metastases (stage II/III)     
   n 352 357   
   2 years 34 (9.7%) 42 (11.8%) 0.81 (0.52,1.28) 0.372
   5 years 64 (18.2%) 81 (22.7%) 0.77 (0.56,1.07) 0.120
Deaths during follow-up (median follow-up, 5.6 years)     
   All patients 98 (18.5%) 129 (23.9%) 0.768 (0.591, 0.999) 0.048
   Stage II/III 82 (23.3%) 110 (30.8%) 0.743 (0.558, 0.989) 0.041
  1. CI, confidence interval.